Skip to content
  • Clinical Studies
  • Schedule M
  • Stability Studies
  • Pharma GMP
  • Pharma Tips
  • Pharma Books
  • Pharma Validation
  • Pharma Regulatory

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • SOP Guidelines
    • SOP Development
    • SOP Training
    • SOP Compliance Monitoring
    • SOP Revision Processes
    • Pharmaceutical SOP templates
    • GMP documentation SOP
    • Data integrity SOP pharma
    • Manufacturing SOP pharmaceutical
    • FDA SOP guidance
    • eQMS SOP workflows
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • GMP Audit Findings
    • Non-Compliance
      • SOP Absence
      • Revision Control
      • Non-Adherence
      • Poor Writing
      • Training Failure
      • Data Integrity Gaps
      • Mismatch Between SOPs and Practice
      • Critical Operations
      • Regulatory Change
      • Emergency Changes
      • Third-Party SOPs
      • Inspection Readiness
      • Deviation Handling
      • CAPA Integration
      • Validation Alignment
      • System Integration
      • Uncontrolled Distribution
      • SOP Implementation Gaps
      • SOP Alignment with Validation
      • Change Control Linkage
  • Toggle search form

Analytical Method Development: Zeta Potential Determination SOP – V 2.0

Posted on By

Analytical Method Development: Zeta Potential Determination SOP – V 2.0

Standard Operating Procedure for Zeta Potential Determination in Analytical Method Development


Department Analytical Method Development
SOP No. SOP/AMD/117/2025
Supersedes SOP/AMD/117/2022
Page No. Page 1 of 14
Issue Date 19/05/2025
Effective Date 20/05/2025
Review Date 19/05/2026

1. Purpose

This SOP defines the method for measuring zeta potential using electrophoretic light scattering (ELS) for pharmaceutical dispersions, nanoparticles, and colloidal systems in order to assess their physical stability and surface charge properties.

2. Scope

This procedure applies to the Analytical Method Development (AMD) laboratory for the characterization of formulations, APIs, and nanoformulations requiring evaluation of zeta potential in both research and product development stages.

3. Responsibilities

  • Analytical Scientist: Prepares samples, conducts measurements, and analyzes data.
  • Instrument Operator: Calibrates equipment and ensures maintenance logs are updated.
  • QA Officer: Reviews and verifies the records for GMP compliance.
  • Head – AMD: Approves method development and interpretation reports.

4. Accountability

The Head of Analytical Method Development is accountable for ensuring method integrity, accuracy, and traceability in zeta potential determination processes.

See also  Analytical Method Development: SOP for In-Vitro Permeation Testing (IVPT) - V 2.0

5. Procedure

5.1 Instrument Preparation

  1. Switch on the zeta potential analyzer (e.g., Malvern Zetasizer Nano ZS) and allow it to stabilize.
  2. Verify the cuvette type:
    • Disposable folded capillary cells (DTS1070)
    • Glass cuvettes (for non-aqueous systems)
  3. Calibrate instrument as per manufacturer’s instructions with 0.1 mM KCl or latex standard solution.
  4. Record in Annexure-1: Instrument Calibration Log.

5.2 Sample Preparation

  1. Prepare the formulation/sample at a concentration ensuring obscuration between 5–10%.
  2. Use freshly prepared or filtered dispersions to avoid particulate interference.
  3. If necessary, dilute with 1 mM electrolyte (e.g., KCl, NaCl) to maintain ionic strength.
  4. Avoid bubbles or precipitates; mix gently to ensure uniformity.
  5. Document preparation in Annexure-2: Sample Preparation Log.

5.3 Measurement Settings

  1. Set parameters:
    • Measurement type: Zeta Potential
    • Medium: Water or selected solvent
    • Temperature: 25°C (unless otherwise justified)
    • Voltage: As per instrument auto-adjust or manual setting (30–150 V)
    • Run duration: 10–20 cycles per sample
  2. Load the sample into the cuvette and place in the holder.
  3. Start measurement and monitor electrophoretic mobility values.
  4. Software will auto-calculate zeta potential via Henry’s equation.
  5. Repeat triplicate readings and report average with standard deviation.
  6. Record results in Annexure-3: Zeta Potential Data Sheet.
See also  Analytical Method Development: Isocratic Method Optimization SOP - V 2.0

5.4 Data Analysis and Interpretation

  1. Evaluate mean zeta potential and standard deviation across triplicates.
  2. Acceptable RSD: ≤ 10% across replicates.
  3. Typical interpretation:
    • > +30 mV or < -30 mV: High stability
    • ±20–30 mV: Moderate stability
    • ±10–20 mV: Low stability
    • < ±10 mV: Likely to aggregate
  4. Include summary in Annexure-4: Interpretation and Observation Sheet.

5.5 Cleaning and Post-Use Protocol

  1. Flush cuvettes with deionized water or ethanol (non-aqueous samples) after use.
  2. Store reusable cuvettes in dust-free containers.
  3. Log cleaning activities in Annexure-5: Post-Use Maintenance Record.

6. Abbreviations

  • ELS: Electrophoretic Light Scattering
  • RSD: Relative Standard Deviation
  • mV: Millivolts
  • SOP: Standard Operating Procedure

7. Documents

  1. Instrument Calibration Log – Annexure-1
  2. Sample Preparation Log – Annexure-2
  3. Zeta Potential Data Sheet – Annexure-3
  4. Interpretation and Observation Sheet – Annexure-4
  5. Post-Use Maintenance Record – Annexure-5

8. References

  • USP General Chapter <790>: Zeta Potential Determination
  • ICH Q6A – Specifications for New Drug Substances
  • Instrument User Manual – Zetasizer Nano Series

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: Instrument Calibration Log

Date Standard Used Expected Value Measured Value Status
18/05/2025 Latex standard -42 mV -41.8 mV Pass

Annexure-2: Sample Preparation Log

Sample ID Formulation Diluent Concentration Prepared By
ZP-117-A API-Nano Dispersion 1 mM KCl 0.5 mg/mL Rajesh Kumar

Annexure-3: Zeta Potential Data Sheet

Trial Zeta Potential (mV) Remarks
1 -31.2 Stable
2 -30.7 Stable
3 -31.5 Stable

Annexure-4: Interpretation and Observation Sheet

Average Zeta Potential: -31.1 mV; RSD: 1.3%. Indicates good colloidal stability and electrostatic repulsion adequate to prevent aggregation.

Annexure-5: Post-Use Maintenance Record

Date Cuvette Type Cleaning Agent Cleaned By Verified By
18/05/2025 Disposable (DTS1070) DI Water Sunita Reddy QA

Revision History:

Revision Date Revision No. Details Reason Approved By
04/05/2025 2.0 Expanded interpretation ranges and added robustness in cleaning protocol Annual Review
See also  Analytical Method Development: SOP for LC-MS/MS Method Development in Impurity Profiling - V 2.0
Analytical Method Development V 2.0 Tags:Analytical Method Development SOP, SOP for analytical calculations, SOP for analytical documentation, SOP for analytical instrument calibration, SOP for analytical instrument qualification, SOP for analytical method change control, SOP for analytical method deviation handling, SOP for analytical method documentation practices, SOP for analytical method lifecycle management, SOP for analytical method optimization, SOP for analytical method risk assessment, SOP for analytical method training and competency, SOP for analytical method transfer protocol, SOP for analytical method validation, SOP for forced degradation studies, SOP for HPLC method development, SOP for limit of detection (LOD) determination, SOP for limit of quantitation (LOQ) determination, SOP for method accuracy testing, SOP for method linearity assessment, SOP for method precision evaluation, SOP for method reproducibility, SOP for method robustness testing, SOP for method transfer, SOP for method verification, SOP for qualification of working standards, SOP for reference standard handling, SOP for specificity testing in analytical methods, SOP for stability indicating methods, SOP for system suitability testing

Post navigation

Previous Post: BA-BE Studies: SOP for Audit Trail Review in Bioanalytical Software – V 2.0
Next Post: API Manufacturing: SOP for QA Review of In-Process Control Records – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Gels V 2.0
  • Injectables V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version